Literature DB >> 27651333

Hepatic FTO expression is increased in NASH and its silencing attenuates palmitic acid-induced lipotoxicity.

Andrea Lim1, Jin Zhou2, Rohit A Sinha3, Brijesh K Singh3, Sujoy Ghosh3, Kiat-Hon Lim4, Pierce Kah-Hoe Chow5, Esther C Y Woon6, Paul M Yen7.   

Abstract

Non-alcoholic steatohepatitis (NASH) is one of the most common causes of liver failure worldwide. It is characterized by excess fat accumulation, inflammation, and increased lipotoxicity in hepatocytes. Currently, there are limited treatment options for NASH due to lack of understanding of its molecular etiology. In the present study, we demonstrate that the expression of fat mass and obesity associated gene (FTO) is significantly increased in the livers of NASH patients and in a rodent model of NASH. Furthermore, using human hepatic cells, we show that genetic silencing of FTO protects against palmitate-induced oxidative stress, mitochondrial dysfunction, ER stress, and apoptosis in vitro. Taken together, our results show that FTO may have a deleterious role in hepatic cells during lipotoxic conditions, and strongly suggest that up-regulation of FTO may contribute to the increased liver damage in NASH.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Fat and obesity associated (FTO) gene; Lipotoxicity; Non-alcoholic steatohepatitis (NASH); Obesity

Mesh:

Substances:

Year:  2016        PMID: 27651333     DOI: 10.1016/j.bbrc.2016.09.086

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  12 in total

1.  Dysregulated m6A modification promotes lipogenesis and development of non-alcoholic fatty liver disease and hepatocellular carcinoma.

Authors:  Yeming Yang; Jingshu Cai; Xue Yang; Kaifang Wang; Kuanxiang Sun; Zhenglin Yang; Lin Zhang; Lu Yang; Chun Gu; Xiang Huang; Ziyan Wang; Xianjun Zhu
Journal:  Mol Ther       Date:  2022-02-19       Impact factor: 12.910

2.  GR-mediated FTO transactivation induces lipid accumulation in hepatocytes via demethylation of m6A on lipogenic mRNAs.

Authors:  Yun Hu; Yue Feng; Luchu Zhang; Yimin Jia; Demin Cai; Shu-Bing Qian; Min Du; Ruqian Zhao
Journal:  RNA Biol       Date:  2020-03-09       Impact factor: 4.652

Review 3.  Critical roles of FTO-mediated mRNA m6A demethylation in regulating adipogenesis and lipid metabolism: Implications in lipid metabolic disorders.

Authors:  Zhou Yang; Guang-Li Yu; Xiao Zhu; Tian-Hong Peng; Yun-Cheng Lv
Journal:  Genes Dis       Date:  2021-01-28

4.  Fat mass and obesity-associated protein promotes liver steatosis by targeting PPARα.

Authors:  Xiaohui Wei; Jielei Zhang; Min Tang; Xuejiao Wang; Nengguang Fan; Yongde Peng
Journal:  Lipids Health Dis       Date:  2022-03-13       Impact factor: 3.876

Review 5.  RNA N6-methyladenosine modification in solid tumors: new therapeutic frontiers.

Authors:  Laleh Melstrom; Jianjun Chen
Journal:  Cancer Gene Ther       Date:  2020-01-20       Impact factor: 5.987

Review 6.  N6-Methyladenosine RNA Modification in Inflammation: Roles, Mechanisms, and Applications.

Authors:  Jiahui Luo; Tao Xu; Kai Sun
Journal:  Front Cell Dev Biol       Date:  2021-06-04

Review 7.  Fat Mass and Obesity Associated (FTO) Gene and Hepatic Glucose and Lipid Metabolism.

Authors:  Tooru M Mizuno
Journal:  Nutrients       Date:  2018-11-01       Impact factor: 5.717

8.  A fluorescent methylation-switchable probe for highly sensitive analysis of FTO N 6-methyladenosine demethylase activity in cells.

Authors:  Adeline Cheong; Joanne J A Low; Andrea Lim; Paul M Yen; Esther C Y Woon
Journal:  Chem Sci       Date:  2018-08-07       Impact factor: 9.825

9.  Fat Mass and Obesity-Associated (FTO) Stimulates Osteogenic Differentiation of C3H10T1/2 Cells by Inducing Mild Endoplasmic Reticulum Stress via a Positive Feedback Loop with p-AMPK.

Authors:  Hyo-Eun Son; Hyeon-Young Min; Eun-Jung Kim; Won-Gu Jang
Journal:  Mol Cells       Date:  2020-01-31       Impact factor: 5.034

10.  Hepatic FTO is dispensable for the regulation of metabolism but counteracts HCC development in vivo.

Authors:  Melanie J Mittenbühler; Katarzyna Saedler; Hendrik Nolte; Lara Kern; Jun Zhou; Shu-Bing Qian; Lydia Meder; Roland T Ullrich; Jens C Brüning; F Thomas Wunderlich
Journal:  Mol Metab       Date:  2020-09-19       Impact factor: 7.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.